Stocks › IBRX
ImmunityBio, Inc.
IBRX·Nasdaq·
United States·USD
$6.02
-0.55 (-8.37%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
IBRX
ImmunityBio, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
IBRXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of IBRX by members of U.S. Congress · 3 on record · 2 in the last 12 months
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Lisa C. McClainHouse · R · MI |
IBRXImmunityBio, Inc. · Stock |
Purchase $1,001 - $15,000 |
Oct 12, 2026 | Sep 30, 2026 | Filing ↗ |
Lisa C. McClainHouse · R · MI |
IBRXImmunityBio, Inc. · Stock |
Purchase $1,001 - $15,000 |
Oct 12, 2026 | Sep 28, 2026 | Filing ↗ |
Daniel S. GoldmanHouse · D · NY |
IBRXImmunityBio, Inc. · Stock |
Sale $1,001 - $15,000 |
Apr 17, 2023 | Mar 6, 2023 | Filing ↗ |
Whale Activity
Position changes in IBRX reported for 2026-09-30 by 456 institutional filers
- Increased146
- New48
- Held96
- Decreased95
- Closed47
- No prior filing24
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 36.1M | $341.0M | increased |
| STATE STREET CORP | 21.1M | $199.1M | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 19.4M | $183.0M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 18.8M | $177.5M | increased |
| D. E. Shaw & Co., Inc. | 10.7M | $101.1M | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 10.6M | $100.1M | increased |
| TWO SIGMA INVESTMENTS, LP | 5.8M | $55.0M | decreased |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 4.9M | $46.6M | increased |
| GOLDMAN SACHS GROUP INC | 4.1M | $39.0M | increased |
| MILLENNIUM MANAGEMENT LLC | 3.8M | $36.0M | decreased |
| UBS Group AG | 3.8M | $35.6M | increased |
| NORTHERN TRUST CORP | 3.7M | $34.9M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by IBRX insiders, by quarter · Form 4
Recent Insider Transactions
124 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Simon Barry J.Director · Director | Sale | −25.0K | $10.75 | $269K | Oct 5, 2026 | Form 4 ↗ |
| Cohen CherylDirector · Director | Sale | −81.1K | $10.50 | $851K | Oct 2, 2026 | Form 4 ↗ |
| Cohen CherylDirector | Sale | −131.2K | $9.50 | $1.2M | Jul 2, 2026 | Form 4 ↗ |
| Cohen CherylDirector | Option exercise | +56.0K | $2.98 | $167K | Jul 2, 2026 | Form 4 ↗ |
| Selecky ChristobelDirector | Sale | −159.5K | $9.02 | $1.4M | Jul 1, 2026 | Form 4 ↗ |
| Selecky ChristobelDirector | Option exercise | +124.4K | $2.99 | $372K | Jul 1, 2026 | Form 4 ↗ |
| Selecky ChristobelDirector | Option exercise | +35.1K | $2.98 | $104K | Jul 1, 2026 | Form 4 ↗ |
| Selecky ChristobelDirector | Sale | −1,000 | $9.00 | $9K | Jun 30, 2026 | Form 4 ↗ |
| Selecky ChristobelDirector | Option exercise | +300 | $2.99 | $897 | Jun 30, 2026 | Form 4 ↗ |
| Selecky ChristobelDirector | Option exercise | +700 | $2.98 | $2K | Jun 30, 2026 | Form 4 ↗ |
| Selecky ChristobelDirector | Sale | −95.7K | $9.01 | $862K | Jun 29, 2026 | Form 4 ↗ |
| Selecky ChristobelDirector | Option exercise | +30.0K | $2.84 | $85K | Jun 29, 2026 | Form 4 ↗ |
| Selecky ChristobelDirector | Option exercise | +33.5K | $2.99 | $100K | Jun 29, 2026 | Form 4 ↗ |
| Selecky ChristobelDirector | Option exercise | +32.2K | $2.98 | $96K | Jun 29, 2026 | Form 4 ↗ |
| Simon Barry J.Director | Sale | −25.0K | $7.88 | $197K | Jun 24, 2026 | Form 4 ↗ |
| Simon Barry J.Director | Sale | −23.0K | $7.18 | $165K | Jun 4, 2026 | Form 4 ↗ |
| CALIFORNIA CAPITAL EQUITY, LLC10% owner | Conversion | +4.6M | $5.43 | $25.0M | Mar 31, 2026 | Form 4 ↗ |
| Simon Barry J.Director | Sale | −75.0K | $12.01 | $901K | Feb 24, 2026 | Form 4 ↗ |
| Selecky ChristobelDirector | Sale | −25.0K | $10.00 | $250K | Feb 23, 2026 | Form 4 ↗ |
| Selecky ChristobelDirector | Option exercise | +25.0K | $2.98 | $75K | Feb 23, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding IBRX · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 12.5M | $109.4M | 1.02% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 11.6M | $101.5M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 9.9M | $86.9M | 0.10% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 8.4M | $73.5M | 0.04% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 4.9M | $42.5M | 0.09% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 3.7M | $32.6M | 0.03% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 3.6M | $31.2M | 0.20% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 4.2M | $30.3M | 0.09% | Jul 31, 2026 |
| iShares Biotechnology ETF iShares Trust | 2.7M | $23.3M | 0.26% | Jun 30, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 2.2M | $17.6M | 0.10% | Aug 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list IBRX's shares (CUSIP 45256X103), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Patrick Soon-ShiongSCHEDULE 13D/A · activist (13D) · 745.5M shares64.8%
Aug 6, 2026 · ↗ - California Capital Equity, LLCSCHEDULE 13D/A · activist (13D) · 106.5M shares10.0%
Aug 6, 2026 · ↗ - Nant Capital, LLCSCHEDULE 13D/A · activist (13D) · 339.5M shares29.6%
Aug 6, 2026 · ↗ - NantWorks, LLCSCHEDULE 13D/A · activist (13D) · 98.5M shares9.3%
Aug 6, 2026 · ↗ - MP 13 Ventures, LLCSCHEDULE 13D/A · activist (13D) · 261.7M shares24.7%
Aug 6, 2026 · ↗ - Cambridge Equities, LPSCHEDULE 13D/A · activist (13D) · 261.7M shares24.7%
Aug 6, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming immunitybio as client
- CONTINENTAL STRATEGY, LLCIMMUNITYBIO, INC. · 2026 Q2—
Filing ↗ - CONTINENTAL STRATEGY, LLCIMMUNITYBIO, INC. · 2026 Q1$60K
Filing ↗ - CONTINENTAL STRATEGY, LLCIMMUNITYBIO, INC. · 2025 Q4 · HCR$60K
Filing ↗ - CONTINENTAL STRATEGY, LLCIMMUNITYBIO, INC. · 2025 Q4 · MED, HCR—
Filing ↗ - THE PETRIZZO GROUP, INC.IMMUNITYBIO, INC. · 2022 Q3 · MED, HCR$45K
Filing ↗
Government Contracts
Federal awards to ImmunityBio, Inc. · USAspending
No federal contract awards found for ImmunityBio, Inc..
U.S. Patents
Recent USPTO applications naming ImmunityBio, Inc.
No USPTO patent applications found for ImmunityBio, Inc..
Annual Financials
From IBRX's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $113.3M | $14.7M | $622K | $240K | $934K |
| Operating income | -$256.0M | -$344.2M | -$362.3M | -$351.3M | -$330.3M |
| Net income | -$351.4M | -$413.6M | -$583.2M | -$416.6M | -$346.8M |
| Diluted EPS | -$0.38 | -$0.62 | -$1.15 | -$1.04 | -$0.89 |
| Operating cash flow | -$304.9M | -$391.2M | -$366.8M | -$337.5M | -$274.4M |
| Cash and equivalents | $88.3M | $143.4M | $265.5M | $104.6M | $181.1M |
| Total assets | $501.9M | $382.9M | $504.5M | $362.4M | $468.9M |
| Total liabilities | $1.00B | $871.1M | $1.09B | $812.2M | $712.8M |
| Shareholders' equity | -$500.5M | -$489.1M | -$587.0M | -$447.3M | -$242.2M |
As ImmunityBio, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 23, 2026 ↗
Stock Splits
Every split and reverse split in the price history
No stock splits in IBRX's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 9.01Results of operationsNov 9, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureNov 9, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureOct 14, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 4, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureJul 30, 2026
EDGAR ↗ - 8-K · Items 5.07, 9.01Shareholder voteJun 10, 2026
EDGAR ↗ - 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureMay 18, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 7, 2026
EDGAR ↗
About ImmunityBio, Inc.
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersSAN DIEGO, CA
IncorporatedDE
SEC CIK0001326110 ↗
Former namesNantKwest, Inc., Conkwest, Inc., ZelleRx Corp


